Undisclosed iNK cell therapy / Century Therap - LARVOL DELTA

Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) - "Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID)... Century Therapeutics...today announced that preclinical data from the Company’s iPSC-derived cell therapy platform will be presented in five posters at the 2024 ASH Annual Meeting to be held in San Diego, CA from December 7-10, 2024...This includes data relating to our enhanced Allo-Evasion via a novel CD300a TASR that demonstrated universal protection from NK cells, advanced CAR endo-domains that improve cytotoxicity and persistence, and differentiation-stage-specific promoters that allow for selective control of gene expression. Furthermore, we are encouraged by data demonstrating our CAR iNK and γδ iT cells’ potent preclinical ability to treat B-cell-mediated autoimmune diseases."

Preclinical • Immunology • Oncology